The utilization of anti-LGR5-ADC to target a smaller subset of potentially quiescent, tumorigenic LGR5+ tumor-initiating cells, which presumably are responsible for recurrence and metastatic progression [38, 63], presents a novel line of therapy for high-grade ER− LGR5high BC. The gene discussed is LGR5; the disease is neoplasm.